CN103239646B - Chinese medicine effective part composition for treating leucoderma and preparation method thereof - Google Patents

Chinese medicine effective part composition for treating leucoderma and preparation method thereof Download PDF

Info

Publication number
CN103239646B
CN103239646B CN201310198014.4A CN201310198014A CN103239646B CN 103239646 B CN103239646 B CN 103239646B CN 201310198014 A CN201310198014 A CN 201310198014A CN 103239646 B CN103239646 B CN 103239646B
Authority
CN
China
Prior art keywords
composition
chinese medicinal
treatment
chinese medicine
medicinal effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310198014.4A
Other languages
Chinese (zh)
Other versions
CN103239646A (en
Inventor
张群
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GUANGZHOU YUNQIAO BIOLOGICAL TECHNOLOGY Co Ltd
Original Assignee
GUANGZHOU YUNQIAO BIOLOGICAL TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GUANGZHOU YUNQIAO BIOLOGICAL TECHNOLOGY Co Ltd filed Critical GUANGZHOU YUNQIAO BIOLOGICAL TECHNOLOGY Co Ltd
Priority to CN201310198014.4A priority Critical patent/CN103239646B/en
Publication of CN103239646A publication Critical patent/CN103239646A/en
Application granted granted Critical
Publication of CN103239646B publication Critical patent/CN103239646B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention discloses a Chinese medicine effective part composition for treating leucoderma. The Chinese medicine effective part composition is prepared from semen oroxyli, medulla of stachyurus, sophora fruit, corn stigma and cortex periplocae as raw materials according to certain parts by weight. The Chinese medicine effective part composition disclosed by the invention can be prepared into a medicament for treating leucoderma. The Chinese medicine effective part composition has the effects of activating blood and removing blood stasis, dredging collaterals and smoothing skin, tonifying liver and kidney, and nourishing the blood to expel wind, can be used for significantly treating the leucoderma, and has the advantages of being free of toxic and side effects, and high in safety.

Description

One is used for the treatment of leukodermic Chinese medicinal effective-part composition and preparation method thereof
Technical field
The present invention relates to Chinese medicine composition field, be specifically related to one and be used for the treatment of leukodermic Chinese medicinal effective-part composition and preparation method thereof.
Background technology
Vitiligo is the abnormal common skin diseases of a kind of metabolism of pigment.Without obvious inducement, doctor trained in Western medicine is thought may be relevant with heredity, autoimmune, endocrine and Nervous and Mental Factors.Due to etiology unknown, treatment is also without desirable method.The conventional therapy of the traditional Chinese medical science is to take TONGQIAOHUOXUE Decoction or LIUWEI DIHUANG TANG, SIWU TANG etc.
Summary of the invention
The object of the present invention is to provide one for the preparation of the leukodermic Chinese medicinal effective-part composition for the treatment of, this Chinese medicinal effective-part composition can be treated vitiligo fast and effectively, has advantages of that therapeutic effect is remarkable, safe, has no side effect.
Above-mentioned purpose of the present invention is achieved by the following technical programs:
The leukodermic Chinese medicinal effective-part composition for the treatment of of the present invention is by making according to the raw material of mass fraction meter as follows: Semen Oroxyli 28, Medulla Stachyuri (Medulla Helwingiae) 25, the Fructus Sophorae 20, Stigma Maydis 15 and Cortex Periplocae 12.
The dosage form that the present invention treats the applicable processing of leukodermic Chinese medicinal effective-part composition is oral liquid.
The preparation method of the leukodermic Chinese medicinal effective-part composition for the treatment of of the present invention comprises the steps:
(1) each Chinese medicinal components is pulverized, added 12 times of water gagings, decoct 3 times, decoct 3 hours at every turn; Filter merging filtrate after decocting liquid, be evaporated to relative concentration and be 1.15 cream, add ethanol, making it contain alcohol amount is 62%, and hold over night reclaims ethanol, concentrated;
(2) concentrated solution after concentrated is added to applicable adjuvant according to conventional formulation technique, be processed into oral liquid.
Compared with prior art, the present invention has following beneficial effect:
(1) compositions of the present invention has effect of nourishing the liver and kidney, yin nourishing hair growth promoting, invigorating qi and benefiting blood, sensible blood stasis dispelling, through test, and can fast treating vitiligo.The present invention is that to make oral liquid for oral administration, compared with traditional external-use lotion or acupuncture and moxibustion treatment, can cure faster vitiligo.
(2) present composition has no side effect.
(3) preparation method of the present composition is simple, and yield is high, has effectively kept the effective ingredient of medicine.
Detailed description of the invention
Further explain the present invention below in conjunction with embodiment, but embodiment does not limit in any form to the present invention.
embodiment 1
Get Semen Oroxyli 28g, Medulla Stachyuri (Medulla Helwingiae) 25g, Fructus Sophorae 20g, Stigma Maydis 15g and Cortex Periplocae 12g, be crushed to coarse powder, add 10 times of water gagings, decoct 3 times, decoct 2 hours at every turn; Filter merging filtrate after decocting liquid, be evaporated to relative concentration and be 1.3 cream, add ethanol, making it contain alcohol amount is 60%, and hold over night reclaims ethanol, obtain concentrated solution 1000ml, get simple syrup, add above-mentioned concentrated solution, and with citric acid adjust pH to 4, adding distil water is to 5000ml, stir, after fine straining, be distributed in 15ml vial, be packaged to be oral liquid.
This product is brown clear liquid, places in half a year and does not produce muddiness, pH approximately 4, total solid 5% left and right.
embodiment 2
Clinical observation patient 600 examples, patient all has obvious vitiligo clinical symptoms and makes a definite diagnosis through clinicist.
Patient is divided into three groups, first group of oral liquid that oral embodiment 1 makes, every day sooner or later respectively once, each 15ml.Take 20 days.Second group of oral TONGQIAOHUOXUE Decoction, dose is followed the doctor's advice.Take LIUWEI DIHUANG TANG for the 3rd group, dose is followed the doctor's advice.
After 20 days, statistical result is in table 1.
Criterion of therapeutical effect: effectively comprise two grades.One-level is that white macula disappears or reduces, and the gross area that recovers the colour of skin is greater than 70%; Secondary be white macula dwindle recover normal colour of skin area be less than 70%, in white macula, have a large amount of pigmentations, grow pigment island or rubescent dimmed person.Invalid referring to after treatment, symptom and sign fail to improve, and even increase the weight of.
Table 1
Group Number of cases Effective Invalid Obvious effective rate (%)
1 200 198 2 99
2 200 101 99 50.5
3 200 124 76 62%
Known by table 1, the oral liquid that embodiment 1 obtains has specially good effect in treatment vitiligo.Chinese medicine of the present invention was made oral liquid after 20 days, can be within half a year highly significant healing or alleviate vitiligo disease and its effect is better than at present conventional TONGQIAOHUOXUE Decoction and LIUWEI DIHUANG TANG.Through follow-up following up a case by regular visits to, all there is not the symptom of recurrence in the above-mentioned patient who takes medicine described in embodiment 1.
embodiment 3
The oral liquid administration ICR mice that uses embodiment 1 to make, body weight 20 ~ 25g, male and female half and half, successive administration 90d.
Through prerun, the lotion toxicity that embodiment 1 makes is very low, does not measure LD50, measures therefore mice is carried out to maximum dosage-feeding on the one.Maximum dosage-feeding is 100ml/d, observes none example and be poisoned to death after 90 days, and all healthy survival, proves that the oral liquid that compositions of the present invention is made can not cause toxic and side effects to human body thus.

Claims (4)

1. the leukodermic Chinese medicinal effective-part composition for the treatment of, is characterized in that by making according to the raw material of mass fraction meter as follows: Semen Oroxyli 28, Medulla Stachyuri (Medulla Helwingiae) 25, the Fructus Sophorae 20, Stigma Maydis 15 and Cortex Periplocae 12.
2. the leukodermic Chinese medicinal effective-part composition for the treatment of according to claim 1, is characterized in that described Chinese medicinal effective-part composition makes oral liquid.
3. the preparation method for the treatment of leukodermic Chinese medicinal effective-part composition described in claim 1 or 2, is characterized in that comprising the steps:
(1) each Chinese medicinal components is pulverized, added 10 times of water gagings, decoct 3 times, decoct 2 hours at every turn; Filter merging filtrate after decocting liquid, be evaporated to relative concentration and be 1.3 cream, add ethanol, making it contain alcohol amount is 60%, and hold over night reclaims ethanol, concentrated;
(2) concentrated solution after concentrated is added to applicable adjuvant according to conventional formulation technique, be processed into oral liquid.
4. the application of Chinese medicinal effective-part composition described in claim 1 or 2, is characterized in that described Chinese medicinal effective-part composition is for the preparation of the leukodermic medicine for the treatment of.
CN201310198014.4A 2013-05-26 2013-05-26 Chinese medicine effective part composition for treating leucoderma and preparation method thereof Expired - Fee Related CN103239646B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310198014.4A CN103239646B (en) 2013-05-26 2013-05-26 Chinese medicine effective part composition for treating leucoderma and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310198014.4A CN103239646B (en) 2013-05-26 2013-05-26 Chinese medicine effective part composition for treating leucoderma and preparation method thereof

Publications (2)

Publication Number Publication Date
CN103239646A CN103239646A (en) 2013-08-14
CN103239646B true CN103239646B (en) 2014-08-06

Family

ID=48919749

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310198014.4A Expired - Fee Related CN103239646B (en) 2013-05-26 2013-05-26 Chinese medicine effective part composition for treating leucoderma and preparation method thereof

Country Status (1)

Country Link
CN (1) CN103239646B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105687358A (en) * 2016-03-30 2016-06-22 王银法 Medicine for treating vitiligo

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1824247A (en) * 2005-12-22 2006-08-30 夏金陵 Composition formula for treating leucoderma and its preparation method
CN102048872A (en) * 2010-11-24 2011-05-11 荣成市新技术应用研究所 Chinese medicinal composition for treating leucoderma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1824247A (en) * 2005-12-22 2006-08-30 夏金陵 Composition formula for treating leucoderma and its preparation method
CN102048872A (en) * 2010-11-24 2011-05-11 荣成市新技术应用研究所 Chinese medicinal composition for treating leucoderma

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
中医治疗白癜风的研究进展;魏飞等;《广西中医药》;20120831;第35卷(第4期);第4-5页 *
中医治疗白癜风证型和方药分析;司富春等;《世界中西医结合杂志》;20121231;第7卷(第8期);第709-712页 *
司富春等.中医治疗白癜风证型和方药分析.《世界中西医结合杂志》.2012,第7卷(第8期),第709-712页.
魏飞等.中医治疗白癜风的研究进展.《广西中医药》.2012,第35卷(第4期),第4-5页.

Also Published As

Publication number Publication date
CN103239646A (en) 2013-08-14

Similar Documents

Publication Publication Date Title
CN104706953A (en) Traditional Chinese medicine preparation for treating chronic cervicitis
CN103239646B (en) Chinese medicine effective part composition for treating leucoderma and preparation method thereof
CN105343847A (en) Traditional Chinese medicine composition for treating eczema containing folium artemisiae argyi and preparing method thereof
CN103239605B (en) Chinese medicine effective part composition for treating hyperostosis and preparation method of Chinese medicine effective part composition
CN106581299B (en) Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof
CN102526385B (en) Medicament for treating climacteric syndrome
CN102526252B (en) Mongolian medicine pillow for treating cervical spondylosis
CN103565986B (en) Chinese medicine active part composition for treating Reynolds disease and preparation method thereof
CN103239543B (en) Chinese medicine effective part composition for treating gastroptosis and preparation method of Chinese medicine effective part composition
CN103239571B (en) Chinese medicine effective part composition for treating alopecia areata and preparation method thereof
CN104435491A (en) Effective part composition of traditional Chinese medicine for treating parkinson disease and preparation method of effective part composition
CN103432247B (en) Traditional Chinese medicine effective part composition for treating ischemic stroke and preparation method thereof
CN103432204B (en) Traditional Chinese medicine effective part composition for treating schizophrenia and preparation method thereof
CN103417900B (en) Composition of effective part of traditional Chinese medicine and preparation method of composition
CN105688139A (en) Traditional Chinese medicine composition for treating scalp folliculitis
CN105796860A (en) Quick-acting bone setting Yi medicine
CN101983712A (en) Novel medicament for treating coronary heart disease
CN105169342A (en) Traditional Chinese medicine composition for treating eczema and preparation method thereof
CN104815132A (en) External lotion for treating low back and leg pain and preparation method
CN103463170B (en) Hyperosteogeny treatment traditional Chinese medicine effective fraction composition and preparation method thereof
CN103432252A (en) Traditional Chinese medicine granule for treating ox influenza and preparation method thereof
CN103239671B (en) Chinese medicine effective part composition for treating climacteric syndrome and preparation method of Chinese medicine effective part composition
CN103432212A (en) Traditional Chinese medicine effective part composition for treating sciatica and preparation method thereof
CN102552503A (en) Traditional Chinese medicine powder used for treating cervical erosion
CN101732408B (en) Chinese medicament for treating angitis and limb angiopathy and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EXPY Termination of patent right or utility model
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140806

Termination date: 20150526